Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy

Sponsor

University of Copenhagen (Other)

Overall Status

Completed

CT.gov ID

NCT02551276

Collaborator

Bispebjerg Hospital (Other), University of Southern Denmark (Other)

Enrollment

Arms

Duration (Months)

Study Details

Study Description

Brief Summary

Studies in animals have shown that beta2-adrenoceptor activation with selective agonists regulates protein metabolism and muscle growth in skeletal and cardiac muscle tissue. These effects may be mediated by cAMP/PKA dependent activation of several downstream sites that modulate protein synthesis and breakdown. While the role of beta2-adrenoceptor signaling is well-described in animals, it is inadequately explored in humans. The purpose of the study is thus to investigate the effect of chronic beta2-adrenergic stimulation (cAMP/PKA-signaling) on muscle hypertrophy.

Condition or Disease	Intervention/Treatment	Phase
Muscle Hypertrophy in Healthy Young Men	Drug: Salbutamol Drug: Placebo Other: Resistance training	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

42 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Investigator, Outcomes Assessor)

Primary Purpose:

Basic Science

Official Title:

Role of 11 Weeks of Beta2-adrenergic Signaling and Resistance Training for Cardiac and Skeletal Muscle Hypertrophy in Men

Study Start Date :

Nov 1, 2013

Actual Primary Completion Date :

Nov 1, 2014

Actual Study Completion Date :

Nov 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Experimental Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks	Drug: Salbutamol Other: Resistance training
Placebo Comparator: Control Placebo and resistance training for 10 weeks	Drug: Placebo Other: Resistance training

Arm

Intervention/Treatment

Experimental: Experimental

Beta2-adrenergic stimulation with salbutamol and resistance training for 10 weeks

Drug: Salbutamol

Other: Resistance training

Placebo Comparator: Control

Placebo and resistance training for 10 weeks

Drug: Placebo

Other: Resistance training

Outcome Measures

Primary Outcome Measures

Skeletal Muscle Hypertrophy (lean body mass in Kilograms) [2 days]
Lean body mass (kg) will be measured at two different days by Dual X-ray absorbance (DXA)

Secondary Outcome Measures

Left Ventricular Hypertrophy (mass in grams) [1 day]
Left Ventricular Mass (g) will be measured by echocardiography of the heart

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 40 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Physical active
Non-smokers
Non-asthmatics
No chronic diseases
Informed consent

Exclusion Criteria:

Smoker
Allergy towards study drug

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

University of Copenhagen
Bispebjerg Hospital
University of Southern Denmark

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Morten Nielsen, Post.Doc, University of Copenhagen

ClinicalTrials.gov Identifier:

NCT02551276

Other Study ID Numbers:

SAL-STYRKE

First Posted:

Sep 16, 2015

Last Update Posted:

Mar 15, 2016

Last Verified:

Mar 1, 2016

Additional relevant MeSH terms:

Hypertrophy

Albuterol

Study Results

No Results Posted as of Mar 15, 2016